Clinical Trial Update: An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients [Phase 2]

View source ↗

Summary

Phase 2 trial updating efficacy and safety of imlifidase for antibody-mediated rejection in kidney transplant patients has completed with results posted in 2024…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant
• Kidney Transplant Rejection

Drugs mentioned

• Imlifidase (imlifidase)

Snippet

Sponsor: Hansa Biopharma AB | Conditions: Kidney Transplant Rejection | Phase 2 | Status: COMPLETED | Results posted: 2024-02-28